Troxerutin Preconditioning and Ischemic Postconditioning Modulate Inflammatory Response after Myocardial Ischemia/Reperfusion Injury in Rat Model
- 326 Downloads
Protective effects of ischemic postconditioning in myocardial ischemia/reperfusion (I/R) injury have been ever demonstrated, but the exact mechanisms remain unclear. Because of their multiplex activities, using natural pharmaceuticals seems to be clinically interesting. The aim of present study was to investigate the effects of troxerutin preconditioning and ischemic postconditioning on inflammatory responses after myocardial I/R injury in a rat model. Twenty-four Wistar rats were divided into four groups as the control, troxerutin receiving (TXR), postconditioning receiving (PostC), and combined therapy (TXR + PostC). Rats’ isolated hearts underwent 30-min LAD regional ischemia followed by 45-min reperfusion. Troxerutin was orally administered for a month before I/R. Ischemic PostC was applied by alternative three cycles of 30-s R/I at the onset of reperfusion. The coronary effluent and ischemic left ventricular samples were used to determine the activities of creatine kinase (CK), intercellular adhesion molecule-1 (ICAM-1), interlukin-1beta (IL-1β), tumor-necrosis factor (TNF-α), and also histopathological studies. Pretreatment of rats with troxerutin significantly reduced myocardial inflammatory cytokines TNF-α and IL-1β levels and ICAM-1 activity after I/R insult compared to those of control I/R hearts (P < 0.05). Application of PostC showed similar impacts on those parameters. In fact, anti-inflammatory mechanisms of both treatments were associated with their protective effects against myocardial damages causing from I/R injury. Pretreatment with troxerutin as well as postconditioning can induce cardioprotection through prevention of the cell-cell interaction and release of inflammatory mediators, minimizing I/R pathological changes in myocardial cells. These two treatments may share same mechanisms in their actions since they showed no significant additive effects.
KEY WORDStroxerutin postconditioning reperfusion inflammation cardioprotection
This study was supported through a grant from Immunology Research Center and Drug Applied Research Center, Tabriz University of Medical Sciences, Iran.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no competing interests.
- 3.Marzilli, M., and A. Huqi. 2010. Cardioprotective therapy in reperfusion injury: lessons from the European Myocardial Infarction Project-Free Radicals (EMIP-FR). Heart and Metabolism 46(1): 35–37.Google Scholar
- 8.Ebrahimi, H., R. Badalzadeh, M. Mohammadi, and B. Yousefi. 2014. Diosgenin attenuates inflammatory response induced by myocardial reperfusion injury: role of mitochondrial ATP-sensitive potassium channels. Journal of Physiology and Biochemistry 64: 393–400.Google Scholar
- 11.Ren, J.Y., J.X. Song, M.Y. Lu, and H. Chen. 2011. Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from diabetic rats: Involvement of transient receptor potential vanilloid 1, calcitonin gene-related peptide and substance P. Regulatory Peptides 169(1): 49–57.CrossRefPubMedGoogle Scholar
- 12.Ferdinandy, P., D.J. Hausenloy, G. Heusch, G.F. Baxter, and R. Schulz. 2014. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacological Reviews 66(4): 1142–1174.CrossRefPubMedGoogle Scholar
- 13.Badalzadeh, R., M. Mohammadi, M. Najafi, N. Ahmadiasl, S. Frajnia, and H. Ebrahimi. 2011. The additive effects of ischemic postconditioning and cyclosporine-A on nitric oxide activity and functions of diabetic myocardium injured by ischemia/reperfusion. Journal of Cardiovascular Pharmacology and Therapeutics 17(2): 181–189.CrossRefPubMedGoogle Scholar
- 16.Vinothkumara, R., R. Vinoth Kumar, V. Karthikkumar, P. Viswanathan, J. Kabalimoorthy, and N. Nalini. 2014. Oral supplementation with troxerutin (trihydroxyethylrutin), modulates lipid peroxidation and antioxidant status in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Environmental Toxicology and Pharmacology 37: 174–184.CrossRefGoogle Scholar
- 19.Lu, J., D. Wu, B. Hu, W. Cheng, Y. Zheng, Z.F. Zhang, Q. Ye, S.H. Fan, Q. Shan, and Y.J. Wang. 2010. Chronic administration of troxerutin protects mouse brain against D-galactose-induced impairment of cholinergic system. Neurobiology of Learning and Memory 93(2): 157–164.CrossRefPubMedGoogle Scholar
- 21.Badalzadeh, R., N. Layeghzadeh, A. Alihemmati, and M. Mohammadi. 2015. Beneficial effect of troxerutin on diabetes-induced vascular damages in rat aorta: histopathological alterations and antioxidation mechanism. International Journal of Endocrinology and Metabolism 13(2): e25969.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Ghyasi, R., G. Sepehri, M. Mohammadi, R. Badalzadeh, and B. Rashidi. 2011. The effect of mebudipine on cardiac function and activity of the myocardial nitric oxide system in ischaemia–reperfusion injury in rats. Cardiovascular Journal of Africa 22(6): 319–323.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Badalzadeh, R., M. Mohammadi, B. Yousefi, S. Farajnia, M. Najafi, and S. Mohammadi. 2015. Involvement of glycogen synthase kinase-3β and oxidation status in the loss of cardioprotection by postconditioning in chronic diabetic male rats. Advanced Pharmaceutical Bulletin 5(3): 321–327.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Jun, L., W. Dong-Mei, Z. Yuan-Lin, H. Bin, C. Wei, Z. Zi-Feng, and L. ad Meng-qiu. 2013. Troxerutin counteracts domoic acid- induced memory deficits in mice by inhibiting CCAAT/enhancer binding protein b-mediated inflammatory response and oxidative stress. The Journal of Immunology 190: 3466–3479.CrossRefGoogle Scholar
- 32.Zhang, Z.F., Y.Q. Zhang, S.H. Fan, J. Zhuang, Y.L. Zheng, J. Lu, D.M. Wu, Q. Shan, and B. Hu. 2015. Troxerutin protects against 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47)-induced liver inflammation by attenuating oxidative stress-mediated NAD+-depletion. Journal of Hazardous Materials 283: 98–109.CrossRefPubMedGoogle Scholar